Trial Profile
Phase 2B, Partially Blinded, Randomized Study in Treatment Naive HCV [hepatitis C virus] G1 to Compare the Efficacy, Safety, and Tolerability of Three Doses of Locteron [interferon alpha-2b] Plus Ribavirin Given Bi-Weekly in Comparison With PEG-Intron [peginterferon-alfa-2B] Plus Ribavirin Given Weekly.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Interferon alpha-2b (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms EMPOWER; SELECT-2
- Sponsors Biolex
- 28 Jun 2012 Planned number of patients changed from 100 to 108 as reported by European Clinical Trials Database.
- 10 May 2011 Results of a preliminary analysis of the sustained virological response rates presented at the Digestive Disease Week 2011.
- 04 Apr 2011 Status changed from active, no longer recruiting to completed.